Nasopharyngeal carcinoma · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | 7.4 mo | 27.9 mo | 6 | R 23 595 PFS proxy | 8 |
DCF Variant #01 | — | R 3 508 | 21d | — | — | 2 | R 7 015 PFS proxy | 1 |
Cisplatin and Epirubicin Variant #01 | — | R 2 911 | 21d | — | — | ~4 | ~R 11 646 PFS proxy · indirect | 1 |
TPC Variant #01 | — | R 2 581 | 21d | — | — | ~2 | ~R 5 163 indirect | — |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 783 | 28d | 20.1 mo | 18.6 mo | 3 | R 5 350 PFS proxy | 3 |
Lobaplatin and Fluorouracil Variant #01 Partial | — | R 607 | 21d | — | — | 2 | R 1 213 PFS proxy | 1 |
No induction Partial | — | — | — | — | — | — | — | 3 |
7 of 7 regimens shown